CS
ITRM

Credit Suisse’s Iterum Therapeutics ITRM Stock Holding History

Credit Suisse’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,333
Closed -$21K – 4383
2020
Q3 		$21K Buy
+1,333
New +$17.8K ﹤0.01% 3985

Other funds holding ITRM

CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $4.62B AUM 29.71% 1-Year Est. Return
SSG
Summit Securities Group New York $810M AUM 27.35% 1-Year Est. Return

Credit Suisse's ITRM Position: Q4 2020 in Review

Credit Suisse sold out of Iterum Therapeutics (ITRM) in Q4 2020, closing a stake of 1,333 shares — an estimated $21K sold.

Credit Suisse first reported a position in ITRM in Q3 2020 and held it in 1 quarter. The position peaked at $21K in Q3 2020. 19 funds tracked by Wall St. Rank hold ITRM as of Q4 2020.

  • Credit Suisse reported no remaining Iterum Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Credit Suisse sold 1,333 Iterum Therapeutics shares in Q4 2020, an estimated $21K.
  • Credit Suisse first reported a position in Iterum Therapeutics in Q3 2020 and held it in 1 quarter.
  • Credit Suisse's Iterum Therapeutics position peaked at $21K in Q3 2020.
  • 19 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2020.

Based on Credit Suisse's 13F filing for Q4 2020, filed 12 Feb 2021.